Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NKTR 
Nektar Therapeutics (NKTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: NKTR (4-star) is a STRONG-BUY. BUY since 57 days. Simulated Profits (68.09%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $96.17
1 Year Target Price $96.17
| 2 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 87.49% | Avg. Invested days 35 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 948.84M USD | Price to earnings Ratio - | 1Y Target Price 96.17 |
Price to earnings Ratio - | 1Y Target Price 96.17 | ||
Volume (30-day avg) 8 | Beta 1.07 | 52 Weeks Range 6.48 - 50.53 | Updated Date 09/16/2025 |
52 Weeks Range 6.48 - 50.53 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -163.17% | Operating Margin (TTM) -320.21% |
Management Effectiveness
Return on Assets (TTM) -31.57% | Return on Equity (TTM) -440.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 869089606 | Price to Sales(TTM) 12.66 |
Enterprise Value 869089606 | Price to Sales(TTM) 12.66 | ||
Enterprise Value to Revenue 11.6 | Enterprise Value to EBITDA -6.5 | Shares Outstanding 19018600 | Shares Floating 17594272 |
Shares Outstanding 19018600 | Shares Floating 17594272 | ||
Percent Insiders 0.71 | Percent Institutions 48.5 |
Upturn AI SWOT
Nektar Therapeutics
Company Overview
History and Background
Nektar Therapeutics was founded in 1990 and is a biopharmaceutical company with a history of pioneering drug delivery technologies. Initially focused on polymer chemistry, it transitioned to developing its own pipeline of drug candidates.
Core Business Areas
- Drug Discovery and Development: Focuses on discovering and developing novel drug candidates using its proprietary polymer conjugation technology platform. This involves research, preclinical studies, clinical trials, and regulatory submissions.
- License and Royalties: Generates revenue through licensing its technology and drug candidates to other pharmaceutical companies, receiving royalties on sales of products developed using its technology.
Leadership and Structure
The company is led by a CEO and a management team responsible for strategic direction and operations. The organizational structure includes departments for research, development, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- NKTR-255 (IL-15 Agonist): An IL-15 agonist immunotherapy being developed for cancer. Competitors include companies developing other IL-15 therapies and immunotherapies like Sanofi and Merck. Clinical trials are underway to assess its effectiveness. Market share is currently 0, pending approval and launch.
- Onzeald (etirinotecan pegol): A topoisomerase I inhibitor approved in Europe for the treatment of adult patients with metastatic breast cancer with brain metastases. Revenue from Onzeald is very limited due to regional restriction of use. Competitors include companies with chemotherapy treatments and targeted therapies like Daiichi Sankyo.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. It is driven by innovation and the need for new and improved therapies for various diseases.
Positioning
Nektar Therapeutics is positioned as a company with expertise in polymer conjugation technology, which it uses to develop novel drug candidates. Its competitive advantage lies in its proprietary technology platform and its ability to improve the efficacy and safety of existing drugs and develop novel therapeutics.
Total Addressable Market (TAM)
The global oncology market is estimated to be in the hundreds of billions of dollars. Nektar's positioning within this TAM is dependent on the success of its pipeline products, especially NKTR-255. However, the total addressable market of Nektar is limited as they are only developing novel drug candidates in niche markets.
Upturn SWOT Analysis
Strengths
- Proprietary polymer conjugation technology
- Experience in drug development
- Potential for improved drug efficacy and safety
- Clinical pipeline
Weaknesses
- Dependence on R&D success
- High cash burn rate
- Limited revenue streams
- Regulatory hurdles
Opportunities
- Partnerships with pharmaceutical companies
- Expansion of pipeline into new therapeutic areas
- Potential for breakthrough therapies
- Advancements in polymer technology
Threats
- Clinical trial failures
- Competition from other biopharmaceutical companies
- Regulatory setbacks
- Patent expirations
Competitors and Market Share
Key Competitors
- LLY
- MRK
- BMY
- AZN
Competitive Landscape
Nektar faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Its advantages lie in its innovative technology and targeted approach to drug development. Its current reliance on pipeline success is a competitive disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Nektar's historical growth has been inconsistent, with periods of significant growth followed by setbacks due to clinical trial failures and partnership dissolutions.
Future Projections: Future growth prospects depend heavily on the success of its pipeline products, particularly NKTR-255 and other ongoing clinical programs. Analyst estimates vary widely due to the inherent uncertainty of biopharmaceutical development.
Recent Initiatives: Recent strategic initiatives include focusing on its core assets, streamlining operations, and exploring partnerships to advance its pipeline.
Summary
Nektar Therapeutics is a biopharmaceutical company with an innovative drug delivery platform but faces significant challenges. Its strengths lie in its technology, but its weaknesses include its reliance on clinical trial success and limited revenue. Success hinges on advancing its pipeline and securing strategic partnerships. Financial performance remains a key area to watch, as cash flow issues will continue to be problematic for the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company website
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biopharmaceutical industry is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nektar Therapeutics
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 1994-05-03 | CEO, President & Director Mr. Howard W. Robin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.nektar.com |
Full time employees 61 | Website https://www.nektar.com | ||
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.